iPS cells to regulate immune graft rejection, The scientists propose a new strategy that uses induced pluripotent stem cells (iPSC) that are induced to regulate the immune response of the transplanted tissue.

The team, led by Professor Ken-chiro Seino from the University of Hokkaido’s Institute of Genetic Medicine, found that thymic epithelial cells derived from mouse-induced pluripotent stem cells (iPSCs) can regulate the immune response to skin grafts by prolonging their activity. iPS cells to regulate immune graft rejection.

The thymus, which is located behind the breastbone, is an important organ for T cell production.

T cells control the immune response, including organ rejection, and are closely linked to immunological self-tolerance, the ability of the immune system to recognize self-produced antigens as non-threatening.

Pluripotent stem cells such as embryonic stem cells (ESC) and iPSC, which are able to differentiate into different cell types, are expected to be alternative sources of graft grafts. However, when the donor’s organ or tissue is transplanted, the graft is rejected by the recipient’s immune system and finally destroyed. The same is true for cells or tissues from potentially multiple stem cells. iPS cells to regulate immune graft rejection.

Because it is important in regenerative medicine to regulate the immune response so that transplantation is successful.

While previous studies have found that it is difficult to efficiently produce thymic epithelial cells from iPSC, the group found that introducing Foxn1, the main thymus gene, into murines, iPSCs helped to effectively differentiate these cells.

Typical epithelial cells originate from iPSC and are imaged with phase contrast microscopy.

The team then transplanted thymic epithelial cells from recipient mice derived from iPSCs and skin grafts from donor mice that were genetically compatible. The results showed that skin grafts in recipient mice lasted longer if thymic epithelial cells derived from iPSC were transplanted. iPS cells to regulate immune graft rejection.

This shows that it is possible to regulate immune rejection by transplanting immune regulatory cells derived from iPSCs before cell or tissue transplantation.

These findings will contribute to the development of regenerative drugs using iPSC cells and tissues, “said Ken-chiro Seino from the research team.